You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 6,168,587


✉ Email this page to a colleague

« Back to Dashboard


Title: Needleless syringe using supersonic gas flow for particle delivery
Abstract:A needleless syringe having a membrane (28) which is ruptured by gas pressure to generate a supersonic gas flow in which particles containing a therapeutic agent are injected.
Inventor(s): Bellhouse; Brian J. (Islip, GB), Sarphie; David F. (Oxford, GB), Greenford; John C. (Abingdon, GB)
Assignee: PowderJect Research Limited (GB)
Filing Date:Dec 05, 1997
Application Number:08/986,124
Claims:1. A method for vaccinating a mammalian subject, said method comprising delivering particles of a powdered agent to said subject via transdermal needleless administration.

2. The method of claim 1, wherein said powdered agent comprises a viral immunogen.

3. The method of claim 2, wherein said powdered agent is a subunit vaccine composition.

4. The method of claim 3, wherein said viral immunogen is a viral protein.

5. The method of claim 3, wherein said viral immunogen is derived from Hepatitis type A.

6. The method of claim 2, wherein said viral immunogen is a viral particle.

7. The method of claim 1, wherein said powdered agent comprises a bacterial immunogen.

8. The method of claim 7, wherein said powdered agent is a subunit vaccine composition.

9. The method of claim 7, wherein said bacterial immunogen is derived from a meningitis immunogen.

10. The method of claim 1, wherein said powdered agent comprises a live, attenuated organism.

11. The method of claim 10, wherein the attenuated organism is a bacterium.

12. The method of claim 11, wherein the attenuated bacterium is Mycobacterium tuberculosis strain Bacille, Calmette, Guerin (BCG).

13. The method of claim 1 wherein the powdered agent is administered sub-cutaneously.

14. The method of claim 1 wherein the powdered agent is administered intra-dermally.

15. The method of claim 1 wherein the powdered agent is administered intra-muscularly.

16. The method of claim 1 wherein the powdered agent comprises a substantially inert carrier.

17. The method of claim 1 wherein the powdered agent comprises a diluent.

18. The method of claim 1 wherein the powdered agent comprises a density-enhancing agent.

19. The method of claim 1 wherein the mammalian subject is human.

20. The method of claim 1 wherein the particles of the powdered agent are delivered to the locus of transdermal needleless administration at a velocity in the range of between 200 and 2,500 m/sec.

21. The method of claim 1 wherein the particles of the powdered agent have a size predominantly in the range of about 0.1 to 250 .mu.m.

22. The method of claim 1 wherein the particles of the powdered agent have a density in the range of 0.48 to 25 g/cm.sup.3.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.